Does Lanreotide work?
Yes, in controlled trials, including one of 204 patients.
The neuroendocrine tumor indication rests on CLARINET, a randomized, double-blind, placebo-controlled trial in 204 patients that showed longer progression-free survival. The acromegaly approval rests on earlier controlled trials summarized in the label. The citations here include one trial and the prescribing information; the open question is how lanreotide compares head to head with octreotide in tumor control, which CLARINET did not test. 12
CLARINET randomized 204 patients to lanreotide or placebo for 96 weeks. All had advanced GEP-NETs that were non-functioning and well or moderately differentiated. Median progression-free survival was not reached with lanreotide. It was 18 months with placebo. That is a 53 percent cut in the risk of progression or death. Overall survival did not differ at the time of analysis. The tumors studied were mostly slow-growing. 1
In acromegaly, the label sums up two randomized studies at several centers. The larger study followed 108 patients for one year. At the last measurement, IGF-1 was in the normal range in 58% of lanreotide patients. Growth hormone was at or below 2.5 ng/mL in 51%. At baseline, those figures were 8% and 0%. 2
Evidence checklist
- Randomised controlled trial CLARINET placebo-controlled trial
- Human study over 100 people CLARINET, 204 patients
- More than one research group Mainly one trial plus label studies
- Clinical outcomes, not surrogate markers Progression-free survival in CLARINET
- Human safety data beyond case reports No excess serious events in 96 weeks
More on Lanreotide
Citations
Reference information only, not medical advice. Drawn from the Lanreotide article, fact-checked against the cited sources. No dosing anywhere on this site.